Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma


The research trainee at Brigham and Women’s Hospital discussed developing RNA constructs to aid with RNA interference.

“The idea is to create in a translational point of view, a platform that could apply to different tumor targeting, specifically the different microRNAs that are down regulated and upregulated in those tumors. So, in our case, we are trying to upregulate 3 of the main downregulated microRNA in the gliblastoma, and at the same time trying to decrease the oncomirs like oncomir 21, and other proteins that are related to the progression of tumors.”

RNA interference may hold potential for tumor multitargeting. New research from Brigham and Women’s Hospital is exploring improving the efficacy and ease of use of RNA interference by developing noncoding, RNA constructs. These constructs can be fit with multiple microRNAs, microRNA sponges and RNA aptamers, each with specific targeting functions.

Feasibility data on the RNA constructs in were presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, held May 7 to 10, 2024, in Baltimore, Maryland, by Debora Mazzetti, MS, research trainee at Brigham and Women’s Hospital and Harvard Medical School.

CGTLive® spoke with Mazzetti to learn more about the potential of RNA constructs in oncological targeting. She shared how she joined the lab of Pier Paolo Peruzzi, MD, PhD at Harvard and discussed their goal of multitargeting downregulated microRNAs in glioblastoma (GBM). She also spoke about further research that the lab is planning to pursue, including improving the RNA constructs to be able to add more targets and target more pathways in GBM.

Click here to read more coverage of the 2024 ASGCT Meeting.

Mazzetti D, Mineo M, Gaiaschi L, et al. Engineering of a Nucleic Acid Platform to Augment RNA Mediated Therapy. Presented at: ASGCT 27th Annual Meeting, May 7-10; Baltimore, Maryland. Abstract #443
Related Videos
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa
Abhishek Gupta, BS, the senior vice president of genetic medicines at Syneos Health
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Luke Roberts, MBBS, PhD, on Early Clinical Data on Congestive Heart Failure Gene Therapy
Lawrence R. Lustig, MD, the chair of the Department of Otolaryngology—Head and Neck Surgery at Columbia University College of Physicians
Casey Maguire, PhD, on Combining Viral-Like Particles and AAV
© 2024 MJH Life Sciences

All rights reserved.